Every 10-Q that Sionna Therapeutics, Inc. (SION) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SION and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SION filings page.
Sionna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on cystic fibrosis, developing NBD1 stabilizers and complementary CFTR modulators. It reported a net loss of $56.7 million for the six months ended June 30, 2026, compared with $34.6 million a year earlier, as R&D and G&A spending increased with pipeline advancement.
Research and development expenses rose to $40.8 million and general and administrative costs to $21.2 million. Cash, cash equivalents and marketable securities totaled $268.3 million, which management expects will fund operations into 2028. Sionna also has an unused $250.0 million at-the-market equity facility and is progressing a Phase 2a trial of SION-719 and a Phase 1 dual-combination trial of SION-451 with complementary modulators.
Sionna Therapeutics reports first-quarter 2026 results showing a net loss of $26.8 million, wider than $16.5 million a year earlier, as it invests heavily in cystic fibrosis drug development. Research and development expenses rose to $19.0 million and general and administrative costs to $10.6 million, both driven mainly by higher headcount and stock-based compensation.
The company ended March 31, 2026 with $289.9 million in cash, cash equivalents and marketable securities and expects this to fund operations into 2028. Sionna is running a Phase 2a trial of NBD1 stabilizer SION-719 as an add-on to Trikafta and a Phase 1 dual-combination trial of SION-451 with two complementary CFTR modulators, with topline data from both studies anticipated in the summer of 2026. It also established a $250.0 million at-the-market equity program but has not yet issued shares under it.
Sionna Therapeutics (SION) filed its Q3 2025 10‑Q, reporting a net loss of $20.3 million for the quarter and $54.8 million year-to-date as it advances cystic fibrosis programs. Cash, cash equivalents and marketable securities totaled $325.0 million as of September 30, 2025, supported by the February IPO.
Quarterly operating expenses were $23.8 million, including research and development $16.0 million and general and administrative $7.8 million. Interest income was $3.5 million. The company completed an IPO at $18.00 per share for net proceeds of approximately $199.6 million, and its preferred stock converted into 27,149,206 common shares. Shares outstanding were 44,628,788 as of October 31, 2025.
Sionna initiated a Phase 2a trial of SION‑719 as an add‑on to standard of care and a Phase 1 dual‑combination study with SION‑451, with topline data anticipated in mid‑2026. Management believes existing liquidity funds operations beyond twelve months and, based on current plans, into 2028.
Sionna Therapeutics is a clinical-stage biopharmaceutical company focused on NBD1 stabilizers for cystic fibrosis. For the six months ended June 30, 2025 the company reported a net loss of $34.6 million and an accumulated deficit of $215.6 million. As of June 30, 2025 it held $337.3 million in cash, cash equivalents and marketable securities and raised $199.6 million net proceeds from its IPO. Outstanding common shares were 44.139823 million as of August 1, 2025.
Clinically, Sionna announced positive topline Phase 1 data in over 200 healthy volunteers for lead NBD1 stabilizers SION-719 and SION-451: both were generally well tolerated with no serious adverse events or dose-limiting toxicities and met exposure thresholds the company believes support further development. SION-719 is planned to advance to a Phase 2a add-on trial pending a drug-drug interaction study and SION-451 will advance to a Phase 1 dual-combination trial; both initiations are anticipated in the second half of 2025. Management states existing resources are expected to fund operations into 2028.